HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48
Benzinga Newsdesk 4 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $47 to $48.
HC Wainwright & Co. analyst Douglas Tsao maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $47 to $48.